Chi-Med Halts Phase III Study Early After Meeting Primary Endpoint

Hutchison China MediTech Limited, better known as Chi-Med, halted a late-stage study early after an interim analysis showed surufatinib hit the primary endpoint of progression-free survival in advanced non-pancreatic neuroendocrine tumors.